Lyell Immunopharma, Inc.

NASDAQ:LYEL

1.27 (USD) • At close November 4, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

20232022202120202019
Operating Activities:
Net Income -234.632-183.118-250.219-204.472-129.377
Depreciation & Amortization 20.2518.0213.6244.2941.256
Deferred Income Tax 4.8362.31739.506-5.612-1.518
Stock Based Compensation 47.08481.92462.20133.26115.732
Change In Working Capital 3.421-82.0154.015-0.336110.808
Accounts Receivables 00000
Inventory 00000
Accounts Payables 1.4640.6670.091-0.2781.709
Other Working Capital 1.957-82.6823.924-0.058109.099
Other Non Cash Items -4.653-6.6834.62411.99142.573
Operating Cash Flow -163.694-169.555-126.249-160.87439.474
Investing Activities:
Investments In Property Plant And Equipment -2.686-24.276-65.504-51.481-16.047
Acquisitions Net -186.734-12.736673.46500
Purchases Of Investments -476.88-406.316-673.465-43.448-34
Sales Maturities Of Investments 663.614419.052617.396686.322238.456
Other Investing Activites 186.73412.736-673.465-864.909-610.842
Investing Cash Flow 184.048-11.54-121.573-273.516-422.433
Financing Activities:
Debt Repayment 00000
Common Stock Issued 2.29.577391.802492.84351.341
Common Stock Repurchased -0.457-0.4610-16.05-0.185
Dividends Paid 00000
Other Financing Activities 2.21.5199.442476.79351.156
Financing Cash Flow 1.74310.635401.244476.79351.156
Other Information:
Effect Of Forex Changes On Cash 00000
Net Change In Cash 22.097-170.46153.42242.4-31.803
Cash At End Of Period 145.931123.834294.294140.87298.472